Authors
Latest:
Juanita Madison on Handling the Provenge ProcessJuanita Madison from the Seattle Cancer Care Alliance on Handling the Provenge Treatment Process
Latest:
Brown Highlights the Rationale for the RAMP-301 Trial in Low-Grade Serous Ovarian CancerDr Brown discusses the rationale for the RAMP-301 trial of avutometinib plus defactinib in low-grade serous ovarian cancer.
Latest:
Dr. Moul on Challenges With Sequencing Therapies for Prostate CancerJudd W. Moul, MD, urologic oncologist, Duke Medicine, discusses challenges with sequencing therapies for prostate cancer.
Latest:
Dr. Moul on Impact of Obesity in Active SurveillanceJudd W. Moul, MD, urologic oncologist, Duke Medicine, discusses a recent study that demonstrated the impact of obesity on active surveillance.
Latest:
Assess, Plan, and Be Flexible for MIPSUnder the new Quality Payment Program, most providers, including community oncologists, are expected to fall under Merit-based Incentive Payment System for the 2017 performance year. With careful analysis and planning, community oncology practices can choose measures that are a good fit and hold the most opportunity for revenue enhancement.
Latest:
Dr. Salerno on Donations to Breast Cancer ResearchJudith A. Salerno, MD, MS, president, CEO, Susan G. Komen, comments on donations to breast cancer research.
Latest:
Prognostic Significance of Post-Treatment PET/CT Following Salvage Re-irradiation of Head and Neck CancersResearchers explored the prognostic significance of PET/CT following re-irradiation in patients with head and neck cancer.
Latest:
Dr. Wolf Discusses the Videssa Breast Blood TestJudith K. Wolf, MD, chief medical officer of Provista Diagnostics, discusses the capabilities of the blood-based diagnostic test Videssa Breast.
Latest:
Paice on Current Pain Management for Breast CancerJudith Paice, PhD, RN, director of the Cancer Pain Program, Division of Hematology-Oncology, and research professor of Medicine, Northwestern University, discusses the pain management for patients with breast cancer.
Latest:
Dr. Trotman Discusses Zanubrutinib in Waldenstrom's MacroglobulinemiaJudith Trotman, MBChB, FRACP, FRCPA, clinical professor of medicine, Concord Clinical School, director of Clinical Research Unit, Haematology Department, Concord Hospital, discusses zanubrutinib in patients with Waldenstrom's Macroglobulinemia.
Latest:
Dr. Trotman on BGB-3111 in Patients With Waldenstrom's MacroglobulinemiaJudith Trotman, MD, clinical associate professor, medicine, Concord Clinical School, The University of Sydney, discusses results of a trial investigating BGB-3111 in patients with Waldenstrom’s macroglobulinemia.
Latest:
Dr Boughey on Defining Optimal Candidates For Surgical De-Escalation in Breast CancerJudy C. Boughey, MD, discusses key characteristics that define the ideal population for surgical de-escalation among patients with breast cancer.
Latest:
Minimizing Axillary Surgery for Patients With Node-Positive Breast CancerAs advances in systemic therapy improve our ability to individualize breast cancer treatment, and improve response rates and outcomes, it is important to reevaluate the most appropriate form of local-regional management.
Latest:
Dr. Wolf on the Design of GEOMETRY mono-1 Trial in METex14-Mutated NSCLCJüergen Wolf, MD, discusses the design and rationale of the phase 2 GEOMETRY mono-1 study with capmatinib (Tabrecta) in METex14-mutated or high MET amplified, advanced non–small cell lung cancer.
Latest:
Dr. Fehniger on Expanding PARP Inhibitors to Other Gynecologic CancersJulia Fehniger, MD, shares her thoughts on the development of PARP inhibitors in ovarian cancer and expansion into other tumor types.
Latest:
Navigating Treatment Choices: Clinically Meaningful Outcomes to Look for in HERTHENA-Lung02This episode discusses the desired outcomes from the HERTHENA-Lung02 trial that would justify using HER3-DXd before platinum and pemetrexed chemotherapy while also exploring the potential benefits of amivantamab, including its PFS advantage and the observed trend toward improved OS in this treatment setting.
Latest:
Next Steps With Obesity-Related Genes in Patients With RCCJulia R. Mendoza-Perez, PhD, visiting scientist, Epidemiology, The University of Texas MD Anderson Cancer Center, discusses next steps and research regarding obesity-related genes in patients with renal cell carcinoma (RCC).
Latest:
Dr. White Discusses Exceptions in the Z11 TrialDr. Julia White from Community Memorial Hospital Discusses Exceptions in the Z11 Trial
Latest:
Future Directions in ALK-Positive and BRAF-Positive NSCLC ManagementPanelists discuss how advancements in targeted therapies and personalized medicine are crucial for addressing the pressing unanswered questions in the management of ALK-positive and BRAF-positive cancers.
Latest:
Dr. von Tresckow on "Sequential Triple-T" Trial in CLLJulia von Tresckow, MD, specialist in oncology, University of Cologne, Department of Internal Medicine, and Center of Integrated Oncology Cologne-Bonn, German CLL Study Group, discusses the CLL2-BIG trial, which explored the combination of obinutuzumab (Gazyva) and ibrutinib (Imbruvica) for induction and maintenance treatment of physically fit and unfit patients with chronic lymphocytic leukemia (CLL). Patients with high tumor burden were given bendamustine as debulking.
Latest:
Dr. White on Research With Regional Nodal Irradiation in Node-Positive Breast CancerJulia R. White, MD, discusses research with regional nodal irradiation in node-positive breast cancer.
Latest:
Julia Whiteker Describes the ONS Breast Care SIGJulia Whiteker Describes the ONS Breast Care SIG Online Community
Latest:
Dr. Adams on Tackling Storage and Logistical Challenges in Cell TherapyJulian Adams, PhD, discusses research efforts surrounding GDA-201, including details of the cryo buffer that the company developed in order to efficiently freeze and recover the GDA-201 cells.
Latest:
Dual Pathways Must Be Targeted in ER-Positive Breast CancerTreating estrogen receptor–positive breast cancer without sparking resistance is a complex endeavor that should involve simultaneously targeting the hormone-signaling and PI3 kinase molecular pathways
Latest:
Prognostic Significance of Post-Treatment PET/CT Following Salvage Re-irradiation of Head and Neck CancersResearchers explored the prognostic significance of PET/CT following re-irradiation in patients with head and neck cancer.
Latest:
Dr. Sosa on Risk Factors for Thyroid CancerJulie Ann Sosa, MD, MA, FACS, FSSO, discusses risk factors for thyroid cancer.
